Downloads Popup Form

Please review our privacy policy so you understand how we collect and use your personal data.

Please review our privacy policy so you understand how we collect and use your personal data.

Dissolution Testing for Orally Inhaled Products: Confronting the Challenges, Realising the Potential

As dissolution testing becomes more prominent in the development of orally inhaled products, our CEO, Jamie Clayton, considers the factors behind its rise and discusses how to build a method that provides reliable and relevant data.

This article is taken from ONdrugDelivery November 2025, Pulmonary & Nasal Drug Delivery, pages 79-83. © Furness Publishing Ltd.

Download PDF
Dissolution Testing for Orally Inhaled Products: Confronting the Challenges, Realising the Potential

You may also be interested in:

Assessing the Performance of a New Apparatus for Orally Inhaled Product Dissolution Testing for the Delivery of Fluticasone Propionate

Developing Robust Orally Inhaled Products to Achieve Better Patient Outcomes

Cascade Impactor Metrics: Exploring New Guidance on Data Analysis

A Q+A With Copley’s Clair Brooks on Alternative BE Approaches in New FDA Guidance

Establishing an Optimal Test Set-up for Delivered Dose Uniformity Testing for Nasal Drug Products

Improving Performance in Inhaled Therapeutics 

Training & Support

Find out more about the broad range of training opportunities and comprehensive support we offer customers

Training

Training

We offer a range of training courses, presentations and seminars covering a wide range of topics Find out more
Servicing

Servicing

A comprehensive range of both in-house and on-site product servicing options are available Find out more
Support

Support

Our team of experienced technicians and engineers are on hand to help and advise Find out more

Downloads

Access the latest product brochures, whitepapers and other useful content

Find out more